Shashi Yadavalli, a principal in Deloitte Consulting's M&A and restructuring practice, will lead the nonprofit's board in Cleveland. The organization says its mission is to 'provide high-achieving students of color from low-income communities the opportunities they need to thrive at top colleges and in high-trajectory careers like STEM, finance, business and law.'
The Dublin, Ireland-based maker of sterilization products with U.S. operations headquartered in Mentor said David Lewis, a board member since 2010, will not stand for election when his term expires on July 29. Replacing Lewis is Paul E. Martin, former senior vice president and chief information officer for Baxter International Inc., who on May 5 was elected to the STERIS board.
Published: Feb 03, 2021
Chief Operating Officer, Dan Carestio, to succeed as President and CEO
DUBLIN, IRELAND, Feb. 03, 2021 (GLOBE NEWSWIRE) Steris Corporation plc (NYSE: STE) (“STERIS” or the “Company”) today announced that Walt Rosebrough, President and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company’s Annual General Meeting. Mr. Rosebrough will remain as CEO Emeritus and Senior Advisor to STERIS’s leadership and Board for the next two years.
STERIS’s Board of Directors has unanimously appointed Dan Carestio, currently Chief Operating Officer (COO), to the Board of Directors as of January 29, 2021 and Mr. Carestio will succeed Mr. Rosebrough as President and CEO, effective July 29, 2021. The board intends to include Mr. Carestio on the slate of Directors for election at the upcoming Annual General Meeting, and Mr. Rosebrough has advised the Board that he does not intend to stand for re-election.
STERIS agrees to buy New Jersey-based Cantel Medical in a deal valued at $4.6 billion
Print
STERIS plc (NYSE: STE), the Dublin-based maker of sterilization products with U.S. operations headquartered in Mentor, has agreed to buy Little Falls, N.J.-based Cantel Medical Corp. (NYSE:CMD) in a deal valued at $4.6 billion.
In a news release issued Tuesday morning, Jan. 12, STERIS said it will acquire Cantel in a cash and stock transaction valued at $84.66 per Cantel common share, based on STERIS closing share price of $200.46 on Monday, Jan. 11. STERIS said that represents a total equity value of about $3.6 billion and a total enterprise value of about $4.6 billion, including Cantel s net debt and convertible notes.
STERIS Announces Definitive Agreement to Acquire Cantel Medical
Complementary to STERIS’s product and service portfolio, focused on infection prevention
Extends STERIS’s reach to Dental Customers
$110 million in expected EBIT synergies by year four
Accretive to adjusted earnings per diluted share in year one
Conference call with STERIS and Cantel management today at 8:00 a.m. ET
DUBLIN, IRELAND and LITTLE FALLS, N.J, Jan. 12, 2021 (GLOBE NEWSWIRE) STERIS plc (NYSE: STE) (“STERIS” or the “Company”) and Cantel Medical Corp (NYSE:CMD) (“Cantel”) today announced that STERIS has signed a definitive agreement to acquire Cantel, through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. Under the terms of the agreement, STERIS will acquire Cantel in a cash and stock transaction valued at $84.66 per Cantel common share, based on STERIS’s closing share price of $200.46 on Janua